<DOC>
	<DOCNO>NCT00481078</DOCNO>
	<brief_summary>This randomized phase II trial study carboplatin , paclitaxel , vorinostat see well work compare carboplatin , paclitaxel , placebo treat patient stage III stage IV non-small cell lung cancer . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Vorinostat may stop growth tumor cell block enzymes need cell growth . It yet know whether give carboplatin paclitaxel together vorinostat effective give carboplatin paclitaxel together placebo treat non-small cell lung cancer</brief_summary>
	<brief_title>Vorinostat , Carboplatin , Paclitaxel Treating Patients With Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare response rate associate combination vorinostat , carboplatin , paclitaxel versus carboplatin , paclitaxel placebo patient previously untreated , advanced NSCLC . SECONDARY OBJECTIVES : I . To determine time progression overall survival two regimen . II . To assess safety profile regimen vorinostat , carboplatin paclitaxel patient advance NSCLC . III . To understand mechanistic aspect drug effect conduct correlative science study peripheral blood , archive tumor tissue , paired biopsy consent patient . OUTLINE : This multicenter , randomize study . Patients stratify accord gender brain metastasis ( present v absent ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive oral vorinostat ( SAHA ) daily day 1-14 paclitaxel IV 3 hour carboplatin IV 30 minute day 3 . Arm II : Patients receive oral placebo daily day 1-14 paclitaxel carboplatin arm l. In arm , treatment repeat every 21 day 4-6 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients must histologically confirm stage IIIB ( malignant pleural pericardial effusion ) stage IV nonsmall cell lung cancer No prior chemotherapy advanced metastatic disease ECOG performance status 0 1 Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan Life expectancy great 12 week Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 X institutional upper limit normal Creatinine within normal institutional limit OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Vorinostat cause fetal harm administer pregnant woman ; adequate wellcontrolled study pregnant woman ; drug use pregnancy , patient becomes pregnant take drug , patient apprise potential hazard fetus Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier Patients may receive investigational agent Patients untreated brain metastasis exclude clinical trial ; however , patient stable brain disease ( corticosteroid ) least 3 week completion appropriate therapy eligible Prior current use valproic acid , HDAC inhibitor Peripheral neuropathy severity great grade 1 Known history allergic reaction paclitaxel Prior therapy paclitaxel Inability take oral medication continuous basis Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study vorinostat HDAC inhibitor potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother vorinostat , breastfeed discontinue mother treated vorinostat ; potential risk may also apply agent use study HIVpositive patient receive combination antiretroviral therapy ineligible potential pharmacokinetic interaction vorinostat ; addition , patient increase risk lethal infection treat marrowsuppressive therapy ; appropriate study undertake patient receive combination antiretroviral therapy indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>